RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · IEX Real-Time Price · USD
2.29
+0.82 (55.78%)
At close: Dec 29, 2023, 4:00 PM
2.28
-0.01 (-0.44%)
After-hours: Dec 29, 2023, 7:59 PM EST
Company Description
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors.
Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors.
The company was founded in 2009 and is headquartered in Los Altos, California.
RenovoRx, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Aug 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Shaun R. Bagai |
Contact Details
Address: 333 W. Santa Clara Street, Suite 900 San Jose, California 95110 United States | |
| Phone | 408-800-2649 |
| Website | renovorx.com |
Stock Details
| Ticker Symbol | RNXT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $9.00 |
| CIK Code | 0001574094 |
| CUSIP Number | 75989R107 |
| ISIN Number | US75989R1077 |
| Employer ID | 27-1448452 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ramtin Agah M.D. | Founder, Chairman of Board and Chief Medical Officer |
| Shaun R. Bagai | Chief Executive Officer and Director |
| James M. Ahlers | Chief Financial Officer |
| Angela Gill Nelms | Chief Operating Officer |
| Ronald B. Kocak CPA | Vice President and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2023 | 8-K | Current Report |
| Nov 27, 2023 | DEF 14A | Other definitive proxy statements |
| Nov 17, 2023 | PRE 14A | Other preliminary proxy statements |
| Nov 14, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Nov 6, 2023 | 8-K | Current Report |
| Sep 11, 2023 | 8-K | Current Report |
| Aug 25, 2023 | 8-K | Current Report |
| Aug 17, 2023 | 8-K | Current Report |
| Aug 16, 2023 | 10-Q | Quarterly Report |